SASPI Ltd.

ORIGINAL ARTICLE   

Implementation of a Clinical Pharmacology-Centric Antimicrobial Stewardship Initiative within COVID-19 Intensive Care Units at a Leading Tertiary Care Referral Center in India

AUTHORS:

Nanda Gamad#, Samiksha Bhattacharjee#, Nusrat Shafiq*, Ashish Bhalla, Kajal K, Bhagat H, et al.

JASPI September 2024/ Volume 2/Issue 3

September 30, 2024

Gamad N, Bhattacharjee S, Shafiq N, Bhalla A,  Kajal K, Bhagat H, et al.Implementation of a Clinical Pharmacology-Centric Antimicrobial Stewardship Initiative within COVID-19 Intensive Care Units at a Leading Tertiary Care Referral Center in India JASPI. 2024;2(3):-22-28 DOI: 10.62541/jaspi042

ABSTRACT

Background: The importance of antimicrobial stewardship during the COVID-19 pandemic remains underreported. 


Methods: We prospectively audited antimicrobial use in COVID-19 ICUs of a tertiary care center from April 2021 to June 2021 during the delta wave of COVID-19 in India. Prospective audits and feedback (PAF) were conducted concurrently during case discussions on all days during this period. A summary of feedback, including empiric antibiotic rationality, de-escalation, etc., was mailed to all the treating physicians every day. 


Results: 161 out of 183 patients (87.97%) were empirically prescribed antibiotics in COVID ICUs, with an average of three antibiotics per patient. The most commonly prescribed empiric antibiotic was piperacillin-tazobactam, followed by ceftriaxone and colistin. De-escalation was suggested in 45.2% of prescriptions, which were followed in 36.5% but delayed in around 16% of suggestions. The presence of multiple comorbidities with intubation and/or shock was the most common reason for initiating and continuing empirical antibiotics. Around 29.8% of the patients on antibiotics developed MDR infections, and Acinetobacter baumannii was the most common organism isolated, with an average length of stay of  20 (19.6 days). 


Conclusion: Antimicrobial stewardship can play an essential role in minimizing the use of unnecessary antimicrobials in COVID-19 patients.  

Share and Enjoy !

Shares
Scroll to Top
If you are interested in joining as a reviewer for JASPI
This is default text for notification bar